Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
This morning, we take an inside look at how Moderna and Merck’s cancer vaccine gamble finally paid off, the FTC takes aim at Amgen’s Enbrel patent strategy, and there’s new proto-FDA guidance for generative AI devices.
Soundtrack for this Readout: Inferno, by Boards of Canada. Yes, it’s weird.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
